Rheumatoid arthritis, anti-tumour necrosis factor treatment, and risk of squamous cell and basal cell skin cancer: Cohort study based on nationwide prospectively recorded data from Sweden

The BMJ

Volumn 352, Issue , 2016, Pages

  Raaschou, Pauline ^a   Simard, Julia F ^b   Hagelberg, Charlotte Asker ^a   Askling, Johan ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; TUMOR NECROSIS FACTOR;

ADULT; AGED; ARTICLE; BASAL CELL CARCINOMA; BOWEN DISEASE; CANCER RISK; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DYSPLASTIC NEVUS; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; INVASIVE SQUAMOUS CELL CANCER; ISCHEMIC HEART DISEASE; JOINT SURGERY; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SKIN DISEASE; SQUAMOUS CELL CARCINOMA; SWEDEN; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; CHEMICALLY INDUCED; PROPORTIONAL HAZARDS MODEL; REGISTER; SKIN NEOPLASMS;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; HUMANS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; REGISTRIES; SKIN NEOPLASMS; SWEDEN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84960194468     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.i262     Document Type: Article

References (30)

1. Balkwill F. Tumour necrosis factor and cancer. Nat Rev Cancer 2009;9:361-71. doi:10.1038/nrc2628.
2. Vajdic CM, Van Leeuwen MT. Cancer incidence and risk factors after solid organ transplantation. Int J Cancer 2009;125:1747-54. doi:10.1002/ijc.24439.
3. Wheless L, Jacks S, Mooneyham Potter KA, Leach BC, Cook J. Skin cancer in organ transplant recipients: More than the immune system. J Am Acad Dermatol 2014;71:359-65. doi:10.1016/j. jaad.2014.02.039.
4. Hartevelt MM, Bavinck JN, Kootte AM, Vermeer BJ, Vandenbroucke JP. Incidence of skin cancer after renal transplantation in The Netherlands. Transplantation 1990;49:506-9. doi:10.1097/00007890-199003000-00006.
5. Lindelöf B, Sigurgeirsson B, Gäbel H, Stern RS. Incidence of skin cancer in 5356 patients following organ transplantation. Br J Dermatol 2000;143:513-9.
6. Zwald FO, Brown M. Skin cancer in solid organ transplant recipients: Advances in therapy and management: Part I. Epidemiology of skin cancer in solid organ transplant recipients. J Am Acad Dermatol 2011;65:253-61, quiz 262. doi:10.1016/j.jaad.2010.11.062.
7. Adami J, Gäbel H, Lindelöf B, et al. Cancer risk following organ transplantation: A nationwide cohort study in Sweden. Br J Cancer 2003;89:1221-7. doi:10.1038/sj.bjc.6601219.
8. Gridley G, McLaughlin JK, Ekbom A, et al. Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 1993;85:307-11. doi:10.1093/jnci/85.4.307.
9. Mellemkjaer L, Linet MS, Gridley G, Frisch M, Møller H, Olsen JH. Rheumatoid arthritis and cancer risk. Eur J Cancer 1996;32A:1753-7. doi:10.1016/0959-8049(96)00210-9.
10. Chakravarty EF, Michaud K, Wolfe F. Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors. J Rheumatol 2005;32:2130-5.
11. Askling J, Fored CM, Brandt L, et al. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis 2005;64:1421-6. doi:10.1136/ard.2004.033993.
12. Dreyer L, Mellemkjær L, Andersen AR, et al. Incidences of overall and site specific cancers in TNF? inhibitor treated patients with rheumatoid arthritis and other arthritides-a follow-up study from the DANBIO Registry. Ann Rheum Dis 2013;72:79-82. doi:10.1136/annrheumdis-2012-201969.
13. Smith KJ, Skelton HG. Rapid onset of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis after starting tumor necrosis factor alpha receptor IgG1-Fc fusion complex therapy. J Am Acad Dermatol 2001;45:953-6. doi:10.1067/mjd.2001.117725.
14. Di Lernia V, Ricci C. Cutaneous malignancies during treatment with efalizumab and infliximab: When temporal relationship does not mean causality. J Dermatolog Treat 2011;22:229-32. doi:10.3109/09546631003681086.
15. Askling J, Fahrbach K, Nordstrom B, Ross S, Schmid CH, Symmons D. Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: Meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. Pharmacoepidemiol Drug Saf 2011;20:119-30. doi:10.1002/pds.2046.
16. Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: Analyses from a large US observational study. Arthritis Rheum 2007;56:2886-95. doi:10.1002/art.22864.
17. Mariette X, Matucci-Cerinic M, Pavelka K, et al. Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: A systematic review and meta-analysis. Ann Rheum Dis 2011;70:1895-904. doi:10.1136/ard.2010.149419.
18. Amari W, Zeringue AL, McDonald JR, Caplan L, Eisen SA, Ranganathan P. Risk of non-melanoma skin cancer in a national cohort of veterans with rheumatoid arthritis. Rheumatology (Oxford) 2011;50:1431-9. doi:10.1093/rheumatology/ker113.
19. Haynes K, Beukelman T, Curtis JR, et al. SABER Collaboration. Tumor necrosis factor ? inhibitor therapy and cancer risk in chronic immune-mediated diseases. Arthritis Rheum 2013;65:48-58. doi:10.1002/art.37740.
20. Socialstyrelsen. Öppna Jämförelser. 2013. www.socialstyrelsen.se.
21. Askling J, Fored CM, Geborek P, et al. Swedish registers to examine drug safety and clinical issues in RA. Ann Rheum Dis 2006;65:707-12. doi:10.1136/ard.2005.045872.
22. Neovius M, Simard J, Sundström A, et al. ARTIS Study Group. Generalisability of clinical registers used for drug safety and comparative effectiveness research: Coverage of the Swedish Biologics Register. Ann Rheum Dis 2011;70:516-9. doi:10.1136/ard.2010.130914.
23. Barlow L, Westergren K, Holmberg L, Talbäck M. The completeness of the Swedish Cancer Register: A sample survey for year 1998. Acta Oncol 2009;48:27-33. doi:10.1080/02841860802247664.
24. Heller RF, Dobson AJ, Attia J, Page J. Impact numbers: Measures of risk factor impact on the whole population from case-control and cohort studies. J Epidemiol Community Health 2002;56:606-10. doi:10.1136/jech.56.8.606.
25. Mercer LK, Green AC, Galloway JB, et al. British Society for Rheumatology Biologics Register Control Centre Consortium British Society for Rheumatology Biologics Register. The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: Longitudinal results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2012;71:869-74. doi:10.1136/annrheumdis-2011-200622.
26. Mercer LK, Davies R, Galloway JB, et al. British Society for Rheumatology Biologics Register (BSRBR) Control Centre Consortium. Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population. Rheumatology (Oxford) 2013;52:91-8. doi:10.1093/rheumatology/kes350.
27. Leombruno JP, Einarson TR, Keystone EC. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: Meta and exposureadjusted pooled analyses of serious adverse events. Ann Rheum Dis 2009;68:1136-45. doi:10.1136/ard.2008.091025.
28. Socialstyrelsen. Cancer incidence in Sweden 2013. www. socialstyrelsen.se/publikationer2014/2014-12-10.
29. Leonardi-Bee J, Ellison T, Bath-Hextall F. Smoking and the risk of nonmelanoma skin cancer: Systematic review and meta-analysis. Arch Dermatol 2012;148:939-46. doi:10.1001/archdermatol.2012.1374.
30. Saevarsdottir S, Wedrén S, Seddighzadeh M, et al. Patients with early rheumatoid arthritis who smoke are less likely to respond to treatment with methotrexate and tumor necrosis factor inhibitors: Observations from the Epidemiological Investigation of Rheumatoid Arthritis and the Swedish Rheumatology Register cohorts. Arthritis Rheum 2011;63:26-36. doi:10.1002/art.27758.